1 / 6

Car-t Cell Therapy Market Is Set To Chart Stellar Growth

In 2017, U.S. FDA approved Tisagenlecleucel (Kymriah), CAR-T cell therapy which is historic in its right. It is used for treating ALL (Acute Lymphoblastic Leukemia) in young adults and children. This happened in August and in October of the year, Yescarta for treating refractory or relapsed diffuse large B-cell lymphomas.<br><br>Read More : https://www.tmrresearch.com/car-t-cell-therapy-market<br><br>View Sample Report : https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6173

apoorvam
Download Presentation

Car-t Cell Therapy Market Is Set To Chart Stellar Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAR-T CELL THERAPY MARKET Global Industry Analysis, Size, Trends, Growth, Trends, and Forecast 2018 - 2028 TMRResearch www.tmrresearch.com

  2. CAR-T CELL THERAPY MARKET 1MARKETOVERVIEW The global CAR-T cell therapy market is set to chart stellar growth owing to an impressive CAGR (Compound Annual Growth Rate) between 2018 and 2028. Multiple factors driving growth in the market, and thus contributing to generation of a plethora of growth opportunities, include increase in incidence of cancer and rising investment in the field of immune oncology. TMRResearch www.tmrresearch.com

  3. CAR-T CELL THERAPY MARKET 2 DEVELOPMENTS In 2017, U.S. FDA approved Tisagenlecleucel (Kymriah), CAR-T cell therapy which is historic in its right. It is used for treating ALL (Acute Lymphoblastic Leukemia) in young adults and children. This happened in August and in October of the year, Yescarta for treating refractory or relapsed diffuse large B-cell lymphomas. TMRResearch www.tmrresearch.com

  4. CAR-T CELL THERAPY MARKET 3KEY TRENDS Number of cases of cancer is going up, leading to a need for better therapies. And, this endeavour for reliable and effective approach is set to drive growth in global CAR-T cell therapy market. It might be pertinent to point out here that the number of patients reporting failure to certain therapies is also leading the global CAR-T cell therapy market onto a higher growth trajectory. TMRResearch www.tmrresearch.com

  5. CAR-T CELL THERAPY MARKET 4REGIONAL OUTLOOK Europe and Asia Pacific will hold a substantial share of the global CAR-T Cell Therapy Market owing to increasing cases of leukemia. North America and Europe will also see growth owing to a large patient pool, better healthcare infrastructure and good levels of awareness. Besides, research and development programs are increasing like that for Kymriah, mentioned above TMRResearch www.tmrresearch.com

  6. TMRResearch www.tmrresearch.com SampleDiscount Check link indescription

More Related